Cougar Biotechnology Announces Presentation of Positive Preclinical Data for CB3304 (Noscapine) in Non-Hodgkin's Lymphoma and Multiple Myeloma.LOS ANGELES -- Cougar cougar: see puma. cougar or puma or mountain lion or panther Species (Puma concolor) of large, graceful cat that lives in a wide variety of habitats in the Americas, from southern Alaska to Patagonia. Biotechnology, Inc., a privately held biotechnology company, today announced the presentation of results from preclinical experiments that demonstrate the effectiveness of the Company's drug CB3304 (noscapine) for the treatment of non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma and multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility . The data was presented as a poster presentation at the American Society of Hematology Annual Meeting in Atlanta, Georgia. The preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. demonstrate that noscapine exhibits potent antitumor an·ti·tu·mor also an·ti·tu·mor·al adj. Counteracting or preventing the formation of malignant tumors; anticancer. Adj. 1. activity against non-Hodgkin's lymphoma and myeloma myeloma /my·elo·ma/ (mi?e-lo´mah) a tumor composed of cells of the type normally found in the bone marrow. giant cell myeloma see under tumor (1). in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. as well as in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. in xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, models. More specifically, the in vitro studies demonstrated that following exposure to noscapine, the OPM See Oracle Process Manufacturing. 2 (multiple myeloma), H9 (T cell lymphoma) and RL (B cell lymphoma) tumor cell lines exhibited an IC50 of approximately 30 nM, 700 nM, and 500 nM for the OPM2, H9 and RL lines respectively. Treatment with noscapine resulted in the induction of apoptosis in each of the cell lines tested. Additionally in vivo studies demonstrated that in xenograft models, daily administration of noscapine resulted in tumor growth delays of between 30-80% of the control tumor volumes. Owen O'Connor, MD, PhD, from Memorial Sloan Kettering Cancer Center stated "Noscapine exhibited marked activity in non-Hodgkin's lymphoma and multiple myeloma cell lines that appears to complement the activity of conventional cytotoxic therapies. As noscapine may represent a new, well-tolerated, oral therapy for the treatment of lymphoma and myeloma, further clinical studies with the drug are warranted." Dr. Arie Belldegrun, MD, FACS FACS Fellow of the American College of Surgeons. FACS abbr. Fellow of the American College of Surgeons FACS fluorescence-activated cell sorter. , Vice Chairman of the Board of Directors of Cougar Biotechnology said, "We are pleased to see the results of these preclinical studies with noscapine. This is the first data to demonstrate the effectiveness of CB3304 (noscapine) in the various subtypes of non-Hodgkin's lymphoma as well as multiple myeloma. We look forward to continued clinical development of the drug in the hematological malignancies." Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology added "This data not only demonstrates CB3304's efficacy in non-Hodgkin's lymphoma and multiple myeloma, but also demonstrates the effectiveness of the drug in combination with other agents that are typically used in the treatment of hematological malignancies. We continue to believe that the drug's preliminary anticancer activity, good tolerability and unique mechanism of action provide strong support for noscapine's continued clinical development." About Cougar Biotechnology Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which has completed Phase I clinical trials in prostate cancer, CB3304, which is currently being tested in a Phase I trial in non-Hodgkin's lymphoma and CB1089, which has been clinically tested in a number of solid tumor types. Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com. This press release contains forward-looking statements that involve risks and uncertainties that could cause Cougar's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Cougar's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Cougar's product candidates, the risk that the results of clinical trials may not support Cougar's claims, Cougar's reliance on third-party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. Cougar assumes no obligation to update these forward-looking statements, except as required by law. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion